John Gever is a freelance writer specializing in medicine and healthcare. His work focuses on medical specialties, with a particular emphasis on topics such as rheumatology, gene therapy, immunology, and immunotherapy. John has been featured in Knowledia, MedPage Today, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
John Gever's coverage primarily focuses on medical research related to autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. He heavily relies on data in his articles. Given the nature of his work, he would likely be interested in hearing from experts who can provide insights into new research findings or clinical data related to autoimmune diseases and their treatment.
As a journalist covering scientific and healthcare topics with a strong emphasis on citing data, John may prefer sources who are actively involved in medical research or have access to significant clinical data that can support the points being made. Additionally, given the technical nature of his reporting, pitches should be tailored towards providing detailed scientific insights rather than general healthcare trends.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Pilot study finds partial B-cell depletion restores DMARD responsiveness
— Failed trial in giant cell arteritis also published the same day
For one of the two, the benefits continue long after treatment stops
By: John Gever
French study posits an answer
Beefed up label warning now appears likely, though events still rare
By: John Gever
Psoriatic arthritis biologics square off, novel molecules and mechanisms, and old drugs made new
By: John Gever
Prospective trial shows reduced immune response but no worsening of underlying disease
Key Takeaways Anifrolumab (Saphnelo) is approved for patients with systemic lupus erythematosus (SLE) and its efficacy for symptom relief has been demonstrated for up to 4 years.
By: John Gever
Quick, ultrasound-based assessment could readily be used in routine practice
— Another case series shows most patients improved markedly after failing everything else
